NEW YORK ( TheStreet) -- CHANGE IN RATINGS Alimera Sciences ( ALM) initiated at Citi with a Buy rating and $15 price target. Several upcoming catalysts for the company's lead product, lluvien. Alimera Sciences ( ALM) initiated at Credit Suisse with an Outperform rating and $16 price target. Alimera's healthcare products can achieve high margins and rapid profitability. Autozone ( AZO) rated new Hold at ThinkEquity. Valuation call, as earnings tailwinds could moderate in the coming quarters. CA ( CA) downgraded at Goldman from Neutral to Sell. $20 price target. Company is facing currency headwinds and is facing a year of strategic transition. Coach ( COH) rated new Buy at ThinkEquity. Management has positioned the company well, with lower price points. Cypress Semiconductor ( CY) rated new Buy at Sterne Agee. $14 price target. Touch handset sales should drive growth. Deere ( DE) upgraded at Morgan Joseph from Hold to Buy. Company seeing higher demand from domestic row farmers and in Brazil. Excel Trust ( EXL) initiated at Barclays with an Overweight rating and $15 price target. The shopping center REIT is well positioned to take advantage of significant buying opportunities over next several years. Great Atlantic & Pacific Tea ( GAP) initiated at Citi with a Hold rating and $6 price target. There could be significant upside if turnaround initiatives begin. Glaxo SmithKline ( GSK) upgraded at Jefferies from Hold to Buy. Company has a strong pipeline and should benefit from currency volatility. Impax Laboratories ( IPXL) downgraded at Wells to Market Perform. Estimates raised, but the stock is already pricing in near-term growth. Jabil Circuit ( JBL) upgraded at UBS from Neutral to Buy. $19 price target. Stock is down 30% over the past two months and appears attractively valued at less than 9 times earnings. Joy Global ( JOYG) upgraded at Goldman from Neutral to Buy. $61 price target. Estimates also raised, as higher mining production should continue to boost CapEx rates. J.P. Morgan ( JMP) upgraded at UBS from Neutral to Buy. $50 price target. Company has a solid footing and the potential to generate above-average earnings growth.
Marriott ( MAR) rated new Neutral at Susquehanna Financial. Stock is already pricing in the company's strong cash flow. Monsanto ( MON) upgraded at Goldman to Buy. Stock was also added to the Conviction List, with a $65 price target. Stock is already discounting poor earnings results. National Semiconductor ( NSM) upgraded at Morgan Keegan from Market Perform to Outperform. Industrial and communications end-markets should benefit from an economic recovery. Royal Caribbean ( RCL) rated new Positive at Susquehanna Financial. $36 price target. Company faces easy comparisons, and could be on the verge of a multi-year recovery. Ralph Lauren ( RL) downgraded at Goldman from Buy to Neutral. Valuation call, based on a $100 price target. Steelcase ( SCS) downgraded at Longbow from Buy to Neutral. $7.50 price target. Valuation call, as the stock is up 32% year-to-date. SPS Commerce ( SPSC) initiated at Thomas Weisel with an Overweight rating and $17 price target. SPSC offers a SaaS-based electronic data integration service, primarily aimed at the consumer packaged goods segment. Tenet Healthcare ( THC) downgraded at Goldman from Buy to Neutral. Stock was also removed from the Conviction Buy list, as the company faces several challenges with its new acquisition bid. $5 price target. Tenet Healthcare ( THC) upgraded at Susquehanna from Neutral to Positive. $6.50 price target. Stock looks oversold, following news of a potential acquisition. Tibco Software ( TIBX) upgraded at Goldman from Sell to Neutral. $12.50 price target. Estimates also boosted, as the company has strong business momentum and will likely buyback more shares. Winn-Dixie Stores ( WINN) initiated at Citi with a Buy rating and $16 price target. WINN's turnaround initiatives should drive productivity, which will lead to improved margins and EPS growth. Watts Water ( WTS) upgraded at Oppenheimer from Underperform to Perform. Commercial markets appear to be at or near a bottom.
Covidien ( COV) price target lower at Barclays to $55 from $60. COV's acquisition of ev3 gives it a franchise in the rapidly-growing neurovascular market. Maintain Overweight rating. Canadian Solar ( CSIQ) price target cut at Barclays to $11 from $22 as the company is under SEC investigation, delaying 1Q10 results. Maintain Equal Weight Rating. Family Dollar ( FDO) target, estimates boosted at BofA/Merrill. FDO price target increased to $50 from $46 on continued broad-based sales strength and margin improvements. Estimates raised through 2012. Reiterate Buy rating. FedEx ( FDX) estimates raised at Goldman through 2012. Air traffic demand and freight rates are improving. Neutral rating and $102 price target. Progress Energy ( PGN) estimates cut at Morgan Stanley through 2012. Company had its rates frozen in Florida. Equal-weight rating and $42 price target. UTI Worldwide ( UTIW) estimates lowered at Morgan Stanley through 2012. Company likely to face a currency headwind in the coming quarters. Equal-weight rating.